An investor in NASDAQ:ITCI shares filed a lawsuit over alleged violations of Federal Securities Laws by Intra-Cellular Therapies Inc.
Investors who purchased shares of Intra-Cellular Therapies Inc (NASDAQ:ITCI) should contact the Shareholders Foundation at [email protected] or call +1(858) 779 – 1554.
The plaintiff claims that between August 12, 2014 through April 28, 2017, the defendants made false and/or misleading statements and/or failed to disclose thatfindings related to toxicity in animals treated with lumateperone (ITI-007) were observed, that these findings posed an additional safety concern regarding lumateperone, and that as a result, Intra-Cellular Therapies’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Those who purchased NASDAQ:ITCI shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego
The post NASDAQ:ITCI Investor News: Lawsuit filed against Intra-Cellular Therapies Inc appeared first on Ground Report.
This post first appeared on 6 Surprising Benefits Of Custom Graphic Design To Build Your Brand, please read the originial post: here